EPISODE · Nov 21, 2024 · 35 MIN
The power of psychedelics meets the power of placebo: ketamine, opioids, and hope in depression treatment | Boris Heifets & Theresa Lii
from From Our Neurons to Yours · host Wu Tsai Neurosciences Institute at Stanford University, Nicholas Weiler
Join us as we dive back into the world of psychedelic medicine with anesthesiologists Boris Heifets and Theresa Lii, who share intriguing new data that sheds light on how ketamine and placebo effects may interact in treating depression.We explore provocative questions like: How much of ketamine's antidepressant effect comes from the drug itself versus the excitement of being in a psychedelics trial? What do we know about how placebo actually works in the brain? And should we view the placebo effect as a feature rather than a bug in psychiatric treatment?Join us as we examine the complex interplay between psychoactive drugs, the brain's own opioid system, and the healing power of hope in mental health care.Related researchPreprint: Opioids Diminish the Placebo Antidepressant Response: A Post Hoc Analysis of a Randomized Controlled Ketamine Trial (medRxiv, 2024)Randomized trial of ketamine masked by surgical anesthesia in patients with depression (Nature Mental Health, 2023)Related episodesPsychedelics, placebo, and anesthetic dreams | Boris Heifets (Part 1) Psychedelics Inside Out: How do LSD and psilocybin alter perception? | Boris Heifets (Part 2)OCD and Ketamine | Carolyn RodriguezPsychedelics and Empathy: Why are psychiatrists taking a fresh look at MDMA? | Rob MalenkaRelated newsResearchers find response to ketamine depends on opioid pathways, but varies by sex (Stanford Medicine, 2024)The rebirth of psychedelic medicine (Wu Tsai Neuro, 2023)Can Psychedelic Drugs Treat Physical Pain? (Scientific American, 2022)Scientists Say A Mind-Bending Rhythm In The Brain Can Act Like Ketamine (NPR, 2020)Get in touchWe're doing some listener research and we want to hear from your neurons! Email us at at [email protected] if you'd be willing to help out, and we'll be in touch with some follow-up questions.Episode CreditsThis episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute. Send us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.We want to hear from your neurons! Email us at at [email protected] more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
Embed this episode
What this episode covers
Join us as we dive back into the world of psychedelic medicine with anesthesiologists Boris Heifets and Theresa Lii, who share intriguing new data that sheds light on how ketamine and placebo effects may interact in treating depression. We explore provocative questions like: How much of ketamine's antidepressant effect comes from the drug itself versus the excitement of being in a psychedelics trial? What do we know about how placebo actually works in the brain? And should we view the placebo...
Ready to play
The power of psychedelics meets the power of placebo: ketamine, opioids, and hope in depression treatment | Boris Heifets & Theresa Lii
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.